PLUS1
8.05
0.04 (0.5%)
0.04 (0.5%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Solid Biosciences Inc | SLDB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.04 | 0.5% | 8.05 | 19:54:25 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.11 | 7.6073 | 8.54 | 7.97 | 8.01 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 7.98 | 8.25 | 0.27 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 6,313 | 737,316 | $ 7.97 | $ 5,875,263 | 3,342,494 | 1.93 - 11.58 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:54:25 | 1 | $ 8.24 | USD |
Solid Biosciences Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 682.43M | 84.77M | 63.19M | $ - | $ - | -2.93 | -3.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Solid Biosciences News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/24/2021 | 16:24 | GlobeNewswire Inc. | Efficacy and Safety Data from Solid Biosciences’ Ongoing.. |
| 2/17/2021 | 07:30 | GlobeNewswire Inc. | Solid Biosciences to Present at Upcoming Investor.. |
| 2/16/2021 | 17:24 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/16/2021 | 16:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/16/2021 | 12:12 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 2/01/2021 | 16:00 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) |
| 1/29/2021 | 16:01 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLDB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 7.01 | 11.58 | 6.65 | 9.35 | 4,446,809 | 1.04 | 14.84% |
| 1 Month | 6.35 | 11.58 | 6.20 | 8.93 | 1,516,752 | 1.70 | 26.77% |
| 3 Months | 3.53 | 11.58 | 3.50 | 6.70 | 2,340,563 | 4.52 | 128.05% |
| 6 Months | 2.61 | 11.58 | 1.93 | 4.62 | 3,188,745 | 5.44 | 208.43% |
| 1 Year | 2.90 | 11.58 | 1.93 | 4.47 | 1,748,834 | 5.15 | 177.59% |
| 3 Years | 29.88 | 54.84 | 1.93 | 7.32 | 965,072 | -21.83 | -73.06% |
| 5 Years | 25.50 | 54.84 | 1.93 | 7.50 | 950,119 | -17.45 | -68.43% |
Solid Biosciences Description
| Solid Biosciences Inc is a life science company. It is engaged in manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |
